Publications by authors named "S Fiorella"
Background: Vedolizumab (VDZ) can be used to treat refractory ulcerative colitis (UC) and Crohn's disease (CD). We assessed whether there are differences in treating UC vs CD with VDZ.
Research Design And Methods: Mayo score in UC and the Harvey-Bradshaw Index (HBI) in CD scored the clinical activity.
Background And Aims: Multiple sclerosis (MS) is associated with osteoporosis, possibly due to neurological disability and decreased calcium intake. The objective of this study was to evaluate the efficacy of a personalized nutritional advice program by a dietitian compared to the delivery of a standard advice form to optimize dietary calcium intake in outpatients with MS.
Methods: We performed a randomized, controlled, parallel trial comparing the efficacy of a personalized dietary advice (PDA) program to standard advice form (SAF) to increase daily calcium intake in MS patients.
Comparison of performances of infliximab biosimilars CT-P13 versus SB2 in the treatment of inflammatory bowel diseases: a real-life multicenter, observational study in Italy.
Expert Opin Biol Ther
February 2022
Background: To compare the performances of Infliximab (IFX) biosimilar CT-P13 and SB2 in the treatment of Inflammatory Bowel Diseases (IBD) outpatients in Italy.
Research Design And Methods: Three hundred and eighty IBD outpatients were retrospectively evaluated. The primary endpoint was to compare the two IFX biosimilars in terms of reaching and maintenance of remission at any timepoint.
Article Synopsis
- Infliximab and adalimumab are both commonly used medications for treating Crohn's disease and ulcerative colitis, and this study aimed to evaluate their long-term effectiveness and safety in real-life clinical settings.
- A total of 712 patients were reviewed, showing that both treatments maintained clinical remission similarly in Crohn's disease, but infliximab showed better results for ulcerative colitis.
- Adalimumab had a significantly lower rate of adverse events compared to infliximab, making it a potentially safer option for patients.
Background: Leishmaniasis is one of the most important vector-borne diseases and it represents a serious world health problem affecting millions of people. High levels of Leishmania infections, affecting both humans and animals, are recognized among Italian regions. Among these, Sicily has one of the highest prevalence of Leishmania infection.
View Article and Find Full Text PDF